Onconetix Inc. Common Stock (ONCO)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate cash, and possess a durable competitive advantage. Onconetix fails almost every test. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $17,120 and net income was -$2.9 million. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $21,457 and net loss was $4.2 million. For fiscal 2025, revenue was $815,371 and net loss was $14.0 million, down sharply from fiscal 2024 revenue of $2.5 million and net loss of $58.7 million. This is not a growing enterprise; it is a shrinking one with enormous losses relative to sales. The company has two employees and sells Proclarix, a prostate cancer blood test, plus licensed products. That may be an interesting niche, but I see no evidence of pricing power, scale, or an economic moat. Licenses with LabCorp and Immunovia are not the same as proprietary demand. Financial health is poor. Trailing free cash flow is -$10.3 million, which is over twenty times the $464,191 market cap at the 2026-10-13 close. FairStock's FCF yield is therefore -2220.6%. The Altman Z-Score is -11.88, a distress signal. Yes, P/B is 0.16 and FairStock's Graham Number is $244.61 with a 99.77% margin of safety, but those book-value measures are not meaningful when the company is losing money and burning cash. Losses in each of the last four years put it in no Lynch category. Growth is negative. I prefer to watch from afar.

In plain English: The company develops a prostate cancer blood test and related cancer products, but it is very small and losing a lot of money. In its latest reported quarter, it brought in only $17,120 in revenue while losing $2.9 million. The stock price looks low compared with some accounting measures, but the business itself looks weak and cash-hungry.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer